Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Recently, Celgene Corporation (CELG - Analyst Report) announced positive results on its candidate apremilast from a phase III study (ESTEEM 1), which evaluated patients suffering from moderate-to-severe chronic plaque psoriasis. The data was presented at the annual meeting of the American academy of dermatology. ESTEEM 1 is Celgene’s first phase III study in the psoriasis indication.

The study evaluated efficacy and safety of the candidate in a range of psoriasis patients. Approximately 33 % of the study population was systemic and/or phototherapy treatment-naïve. Almost 30% of the overall study population had undergone prior biologic therapy.

Data from the study revealed that approximately 33.1% patients in the apremilast arm demonstrated a 75% reduction in their PASI (psoriasis area and severity index) score at week 16 as opposed to only 5.3% in the placebo arm. Moreover, the candidate was well tolerated in the study and was found to be safe

Celgene intends to seek US approval for apremilast in the psoriasis indication in the second half of 2013. The company is also evaluating apremilast in patients suffering from psoriatic arthritis. It intends to seek US approval for apremilast in the psoriatic arthritis indication shortly.

European approval for apremilast in the psoriasis and psoriatic arthritis indications (combined) is expected to be sought in the second half of 2013. The candidate is also undergoing phase III studies in the ankylosing spondylitis indication. The data is expected in 2014.

Celgene, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Biopharma stocks, such as Array Biopharma (ARRY - Snapshot Report), Celldex Therapeutics, Inc. (CLDX - Snapshot Report) and Kythera Biopharmaceuticals, Inc. (KYTH - Snapshot Report) are comparatively well placed and carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%